NKGN vs. MOLN, VIGL, SGMO, DBVT, OMGA, BLUE, CGTX, ATHA, JATT, and PLX
Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Molecular Partners (MOLN), Vigil Neuroscience (VIGL), Sangamo Therapeutics (SGMO), DBV Technologies (DBVT), Omega Therapeutics (OMGA), bluebird bio (BLUE), Cognition Therapeutics (CGTX), Athira Pharma (ATHA), JATT Acquisition (JATT), and Protalix BioTherapeutics (PLX). These companies are all part of the "biological products, except diagnostic" industry.
NKGen Biotech (NYSE:NKGN) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
Molecular Partners received 11 more outperform votes than NKGen Biotech when rated by MarketBeat users.
NKGen Biotech has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.
NKGen Biotech has a net margin of 0.00% compared to Molecular Partners' net margin of -864.73%. NKGen Biotech's return on equity of 0.00% beat Molecular Partners' return on equity.
Molecular Partners has higher revenue and earnings than NKGen Biotech.
76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, NKGen Biotech had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for NKGen Biotech and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.88 beat NKGen Biotech's score of 0.69 indicating that Molecular Partners is being referred to more favorably in the news media.
Molecular Partners has a consensus price target of $4.50, suggesting a potential upside of 18.42%. Given Molecular Partners' higher probable upside, analysts clearly believe Molecular Partners is more favorable than NKGen Biotech.
Summary
Molecular Partners beats NKGen Biotech on 7 of the 13 factors compared between the two stocks.
Get NKGen Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NKGen Biotech Competitors List
Related Companies and Tools
